4//SEC Filing
Combs Andrew 4
Accession 0001562180-24-008565
CIK 0001678660other
Filed
Dec 25, 7:00 PM ET
Accepted
Dec 26, 7:49 AM ET
Size
7.2 KB
Accession
0001562180-24-008565
Insider Transaction Report
Form 4
Combs Andrew
Chief Chemistry Officer
Transactions
- Purchase
Common Stock
2024-12-20$1.15/sh+3,075$3,536→ 317,623 total - Purchase
Common Stock
2024-12-23$1.37/sh+60,000$82,002→ 377,623 total
Footnotes (2)
- [F1]The reported total includes 10,106 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Documents
Issuer
Prelude Therapeutics Inc
CIK 0001678660
Entity typeother
Related Parties
1- filerCIK 0001825005
Filing Metadata
- Form type
- 4
- Filed
- Dec 25, 7:00 PM ET
- Accepted
- Dec 26, 7:49 AM ET
- Size
- 7.2 KB